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Abstract Among the various biomarkers that are used to di-
agnose or monitor disease, extracellular vesicles (EVs) repre-
sent one of the most promising targets in the development of
new therapeutic strategies and the application of new diagnos-
tic methods. The detection of circulating platelet-derived
microvesicles (PMVs) is a considerable challenge for labora-
tory diagnostics, especially in the preliminary phase of a dis-
ease. In this study, we present a multistep approach to
immobilizing and detecting PMVs in biological samples
(microvesicles generated from activated platelets and human
platelet-poor plasma) on functionalized silicon substrate. We
describe the application of time-of-flight secondary ion mass
spectrometry (TOF-SIMS) and spectroscopic ellipsometry
methods to the detection of immobilized PMVs in the context
of a novel imaging flow cytometry (ISX) technique and atom-
ic force microscopy (AFM). This novel approach allowed us
to confirm the presence of the abundant microvesicle
phospholipids phosphatidylserine (PS) and phosphatidyletha-




also detected. Moreover, we were able to show that
ellipsometry permitted the immobilization of PMVs on a func-
tionalized surface to be evaluated. The sensitivity of the ISX
technique depends on the size and refractive index of the an-
alyzed microvesicles.
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Introduction
Among the various biomarkers that are used to diagnose and
monitor cardiovascular disease and its complications, extra-
cellular vesicles (EVs) appear to be one of the most promising
targets in the development of new therapeutic strategies and
the application of new diagnostic methods [1–3]. Elevated
levels of EVs (also called microvesicles or microparticles)
have been detected in patients with unstable angina, myocar-
dial infarction, or vascular complications of diabetes mellitus
[2, 4, 5]. Most circulating blood EVs originate from platelets,
and are therefore usually termed platelet-derived
microvesicles (PMVs). They are produced during platelet ac-
tivation—a physiological process that leads to hemostasis and
blood coagulation. As first demonstrated almost two decades
ago by Heijnen et al., activated platelets release two classes of
membrane vesicles: the dominant larger type (100–500 nm in
size), known as microvesicles, emerge from the platelet sur-
face in a shedding process, whereas a much smaller type
(< 100 nm), named exosomes, are produced during exocytosis
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[6]. PMVs are postulated to play an important role in throm-
bus formation and in strengthening clot structures [7].
Detecting circulating PMVs during the preliminary phase
of a disease is a considerable challenge for laboratory diag-
nostics. Despite the availability and accessibility of flow cy-
tometry methods in routine hematology laboratories, most
clinical cytometers still have resolutions of around 500 nm.
The use of high-sensitivity flow cytometry permits greater
analytical resolution, allowing EVs to be resolved down to
400 nm in diameter using a forward scatter detector [8, 9].
The other strategy is to apply the novel method of imaging
flow cytometry; for example, to use the ImageStreamX Mark
II imaging cytometer (ISX), which provides increased sensi-
tivity for smaller EVs. Visual examination of every event that
passes through the flow cell allows objects smaller than the
optical resolution cut-off of 200 nm to be resolved [10, 11].
Nevertheless, novel label-free methods to detect and quan-
tify PMVs are now available. The use of electrochemical
potential-modulated electrochemical impedance spectroscopy
(EIS) [12] and other methods that utilize the Coulter principle
to determine the absolute size distribution of vesicles in sus-
pension, such as resistive pulse sensing (RPS) [13, 14] and
surface plasmon resonance spectroscopy [15], have recently
been proposed. Another innovative label-free optical method
is grating coupled interferometry (GCI). This sensing system
combines the cost-effectiveness, simplicity, and reliability of
grating coupled planar optical waveguides with the excellent
resolution of interferometric measurements [16]. However,
the complexity of body fluids (e.g., whole blood or plasma)
still limits such methods to specific applications based on
immunodetection techniques.
The main approach used in routine diagnostics is to avoid
interference from abundant proteins such as fibrinogen, albu-
mins, immunoglobulins, and trypsin inhibitors. In this ap-
proach, immobilizing EVs, especially those generated by
platelets, improves the accuracy/fidelity of biosensor-based
methods of detecting PMVs [17].
The motivation for the present study was to develop a one-
step procedure for detecting EVs that was based on the lab-on-
a-chip approach. The first goal was to generate a functional-
ized surface onto which PMVs are immobilized to facilitate
their detection. The second goal was to visualize these
immobilized PMVs as appreciable objects and detect them
using time-of-flight secondary ion mass spectrometry (TOF-
SIMS) and spectroscopic ellipsometry.
In order to achieve these goals, the conventional
method of modifying s i l icon subst ra tes wi th 3-
g lyc idoxypropyl ( t r imethoxys i lane) (GOPS) and
functionalizing with PAC-1 antibody was applied. The
PAC-1 antibody recognizes an epitope on the platelet-
specific glycoprotein IIb/IIIa (gpIIb/IIIa, αIIbβ3) complex
which is exposed on activated platelets and carried by PMVs
[4, 18]. This antibody was previously used to functionalize a
graphene-oxide-based electrochemical biosensor for detect-
ing PMVs [17]. In our work, TOF-SIMS analysis was ap-
plied to demonstrate the complementary analysis of EV lipid
composition. This combined approach is extended in the
present work, as we adopted the novel technique of imaging
flow cytometry (ISX, using an ImageStreamX Mark II im-
aging cytometer) as well as atomic force microscopy (AFM)
for EV enumeration and characterization [10, 14]. The ad-
vantage of ISX is that it facilitates the visual examination of
every single object that passes through the flow cell.
Additionally, ISX can detect fluorescent signals from micro-
particle populations, even when they are smaller than the
optical resolution cut-off of 200 nm [11].
The novelty and significance of this approach is that it
is a one-step procedure for detecting and profiling lipids
in immobilized EVs derived from both human plasma
and activated platelets (PMVs). Our work is also original




Silicon wafers with native oxidized silicon layers (SiOx) were
f rom Si-Mat (Kaufer ing , Germany) . Chemica l s
used were EGTA and analytical-grade chloroform
(POCH, Gliwice, Poland); bovine serum albumin
(BSA; cat. no. A2153), glucose, MES, MgCl2, NaCl, 3-
glycidoxypropyl(trimethoxysilane) (GOPS; cat. no.
440167), PBS (cat. no. 4417), Triton X-100 (cat. no.
9002-93-1), and FITC (fluorescein isothiocyanate)-labeled
phalloidin (cat. no. P5282) (Sigma–Aldrich, Munich,
Germany); bovine thrombin (Bio Trombina 400, Biomed-
Lublin, Lublin, Poland); ethanol, formaldehyde, and tolu-
ene (Chempur, Karlsruhe, Germany); phospholipids (1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)
and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine
sodium salt (POPS), cat. nos. 850457P and 840039P, re-
spectively; Avanti Polar Lipids, Inc., Alabaster, AL, USA);
flow cytometry antibodies and reagents (annexin V Pacific
BlueTM conjugate (cat. no. A35122, Molecular Probes Life
Sciences, Paisley, UK), Alexa Fluor® 647 anti-human
CD61 antibody and phycoerythrin (PE) conjugated anti-
human CD9 antibody (cat. nos. 336408 and 312106, re-
spectively; BioLegend Inc., San Diego, CA, USA), and
PAC-1 (cat. no. 340535, BD-Bioscience, Erembodegem,
Belgium)); and flow cytometry standardization kits
(SpheroTM Flow Cytometry Nano Fluorescent Size
Standard Kit (cat. nos. NFPPS-52-4K, NFPPS-0152-5,
Spherotech Inc., Lake Forest, IL, USA)).
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Sample collection and PMV preparation
Blood samples for platelet-rich plasma (PRP) preparation
were collected in duplicate according to a standardized proto-
col using the S-Monovette individual blood collection system
(Sarstedt AG & Co., Nümbrecht, Germany) from healthy do-
nors (n = 3) in the morning (8–11 am) after overnight fasting.
The second tube, containing citrate 0.106 M anticoagulant
(8.2 mL, cat. no. 01.1606.001), was used for PRP preparation.
After phlebotomy, samples were subjected to centrifugation
by a Z300K centrifuge (Hermle Labortechnik, Wehingen,
Germany) at 165×g for 10 min to acquire PRP. After that,
platelets were pelleted at 750×g for 10 min and twice washed
with JNL buffer without Ca2+ (130 mMNaCl, 10 mM sodium
citrate, 9 mM NaHCO3, 6 mM D-glucose, 0.9 mM MgCl2,
0.81 mM KH2PO4, and 10 mM Tris, pH 7.4). To obtain
thrombin-generated PMVs, the washed platelets were resus-
pended in 0.5 ml of JNL buffer with 1.8 mM CaCl2 and 1 IU
of bovine thrombin (Biomed-Lublin) and incubated for
30 min at 37 °C. After that, the activated platelets were
pelleted and the supernatant containing PMVs was subjected
to further investigations. Additionally, platelet-poor plasma
(PPP) was collected according to protocol A, in which the first
centrifugation was performed at 2500× g for 15 min at room
temperature with a light brake, before the separated plasma
was transferred to a new centrifugation tube and centrifuged
again as above [19].
Fluorescent microscopy observations of platelets Washed
platelets were incubated on prepared siliconized (A) and
collagen-coated (B, C) microscopy cover slips in a humidified
chamber (30 min at 37 °C). After that, unattached platelets
were rinsed three times with a cytoskeleton buffer (CB;
10 mM MES, 150 mM NaCl, 5 mM EGTA, 5 mM MgCl2,
5 mM glucose; pH 6.1), fixed with 3.7 % formaldehyde in a
phosphate-buffered saline solution (PBS), and finally perme-
abilized with 0.1 % Triton X-100 in PBS for 30 min. The F-
actin cytoskeleton was visualized using FITC-labeled
phalloidin. Each coverslip was incubated with 15 μl of this
phalloidin-FITC in CB (500 ng/ml) for 15 min at 37 °C in a
humidified chamber. After three washes with CB, the stained
platelets were observed using an Axiovert 200 fluorescent
microscope (Carl Zeiss, Jena, Germany) at 630×
magnification.
PMV enumeration and visualization PMVs were counted
and characterized using an imaging flow cytometry (ISX) sys-
tem (ImageStreamX Mark II, Amnis Corporation, Seattle,
WA, USA) equipped with four lasers (wavelengths: 405,
488, 642, and 785 nm), and the resulting data were analyzed
with the IDEAS 6.0 software package (Amnis Corporation).
During calibration and in experiments with biological materi-
al, a maximum power of 200 mW was used for the blue laser
(488 nm), 150 mW for the red laser (642 nm), 120 mW for the
violet laser (405 nm), and 70 mW for the 785 nm laser (SSC).
Pictures were collected at the highest optical magnification
(60×) with a numerical aperture of 0.9 and an image resolution
of approximately 0.3 × 0.3 microns/pixel [10]. Since the ISX
system was equipped with two CCD sensors (each with six
channels of signal detection), two channels of transmitted light
(bright field, BF) were required to achieve spatial coordination
between the matrices. The intensity of the background for the
BF channel was set to 800 for both matrices. Acquisition was
performed for 5,000 objects. Calibration for MVs was per-
formed using SpheroTM Flow Cytometry Nano Fluorescent
Size Standard Kits, including five categories of microbeads
(0.13, 0.22, 0.45, 0.88, and 1.33 μm in diameter) labeled with
FITC to avoid interference when linking with the acquired
files. Five microliters of PMV suspension diluted up to
150 μl volume in PBS and annexin V binding buffer.
Then, 5 μl of each antibody and annexin V were added
and the mixture was incubated at room temperature for
15 min. The acquired files were virtually merged with the
previous calibrator data files and analyzed with the IDEAS
software package.
Preparation of multilamellar and unilamellar liposomes
Multilamellar and/or unilamellar liposomes consisting of
POPC (1 mM) alone or POPC (0.95 mM) and POPS
(0.05 mM) were prepared according to previously described
methods [20–22]. Briefly, a mixture of the selected lipids at
desired concentration was dissolved in chloroform saturated
with argon to prevent oxidation. Chloroform was then evapo-
rated with a stream of argon/nitrogen gas, and the lipid film
that formed on the bottom of the test tube was thoroughly
dried under reduced pressure for 12 h. A buffer solution was
added to the dried lipids at a temperature higher than the main
phase-transition temperature of the lipids used (room temper-
ature was appropriate for the lipids used in this work), and the
mixture was vortexed vigorously. To obtain unilamellar lipo-
somes, the suspension was extruded using an extruder with
needles (cat. no. 610000, Avanti Polar Lipids, Inc.) and fil-
tered using filters with pore diameters of 0.1 μm and 0.2 μm
(cat. nos. 610005 and 61006, Whatman, GE Healthcare Ltd.,
Little Chalfont, UK) above the phase-transition temperature of
the lipids. The size distribution and stability of the liposomes
were analyzed in 10× dilution using a Zetasizer Nano S parti-
cle size analyzer (Malvern Instruments, Malvern, UK).
Surface functionalization to facilitate the immobilization
of PMVs
Next, a multistep method was carried out to functionalize the
silicon surface with PAC-1 antibodies, thus promoting the
immobilization of PMVs. In the first step, Si substrates were
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washed with ethanol and toluene and then cleaned and
hydrophilized with oxygen plasma. The second step involved
silanizing the substrates by immersing them in 1 % (v/v)
GOPS in anhydrous toluene for 1 h, washing the substrates
in a sequence of toluene and ethanol baths, and finally drying
them under a stream of N2. Modification of the silicon surface
with epoxysilane facilitated direct covalent bonding to pro-
teins (antibodies) [23]. In the third step, PAC-1 antibodies
were immobilized on the silanized silicon substrates by incu-
bating them in a 100 μg/mL solution of PAC-1 in PBS
(pH 7.4) for 24 h. After the incubation and washing steps,
blocking was performed in the fourth step by incubating the
substrates in BSA (10 mg/mL) for 1 h. Finally, the function-
alized surfaces were incubated for 1 h with human plasma or
PMVs from activated platelets. As a negative control, sub-
strate samples were incubated with 100 μg/mL BSA for
24 h instead of incubating with PAC-1 (stage 3), and then
stages 4 and 5 were performed. All substrates were washed
with PBS buffer and distilled water and dried under a stream
of N2 before surface characterization.
Surface characterization
Atomic force microscopy Topographic micrographs of sur-
faces silizanized with GOPS, functionalized with PAC-1 anti-
bodies, blocked, and with PMVs immobilized on them were
recorded in air using an Agilent (Santa Clara, CA, USA) 5500
microscope working in a noncontact mode. AFM probes with
a spring constant of 2 N/m, a tip radius of <7 nm, and a
resonant frequency of about 70 kHz were used. For all sam-
ples, the mean height distribution in the AFM image and the
doubled width at half-maximum of a radially averaged auto-
correlation function were taken as the AFM height and feature
size, respectively [24, 25]. In turn, for the surface exposed to
PMVs, the AFM height and feature size were estimated from
cross-sections through n = 25 individual microvesicles visual-
ized on AFM images. AFM images were analyzed with the
WSxM software provided by Nanotec Electronica S.L. [26]
(downloadable at http://www.nanotec.es).
Spectroscopic ellipsometry The effective ellipsometric thick-
ness of the molecular overlayer on each silicon substrate after
the successive modification and immobilization steps was
evaluated with a Sentech (Berlin, Germany) SE800 spectro-
scopic ellipsometer. Spectra of two ellipsometric angles (Ψ
and Δ) relating to the amplitude of and phase difference be-
tween the parallel and perpendicular components of the polar-
ized light beam following reflection from a surface were re-
corded. The measurements were performed over the wave-
length range 320–700 nm and at a fixed angle of incidence
of 70°. Results were analyzed with the SpectraRay 3 software.
The effective thickness of the molecular layer was estimated
by fitting a model assuming uniform layers to each pair of
ellipsometric angles. This uniform-layers model used the
Cauchy dispersion model, which describes the refractive in-
dex (n) as a function of the wavelength (λ): n = A+ B/λ2 +C/
λ4. A three-layer model (silicon substrate/mixed SiOx and
GOPS layer/protein layer/PMVs overlayer) was applied.
Fixed refractive index values of n = 3.87 for Si, n = 1.46 for
both SiOx and GOPS [27, 28], n = 1.53 for biomolecules (pro-
teins and lipids) [29–31], and n = 1.39 for PMVs [8, 32] were
used. A mixed SiOx and GOPS layer of constant thickness
2.88 ± 0.14 nm (value obtained from fitting measurements
performed on a bare GOPS-modified silicon substrate) was
assumed in order to fit the thickness of the biomolecular layer.
Time-of-flight secondary ion mass spectrometry After
functionalization and PMVimmobilization, surface molecular
composition analysis of the silicon substrates was performed
using a TOF.SIMS 5 instrument (ION-TOF GmbH, Münster,
Germany) equipped with a 30-keV bismuth liquid metal ion
gun. Bi3
+ clusters were used as primary ions, applying an ion
dose density of <1012 ion/cm2 to ensure static mode condi-
tions. A low-energy electron flood gun was used for charge
compensation. Positive high-resolution mass spectra (with
minimal mass resolution (m/Δm) > 6000 at C4H5
+) were ac-
quired from several nonoverlapping 100 μm × 100 μm re-
gions (with a resolution of 128 × 128 points). The TOF-
SIMS data were normalized with respect to the total ion
intensity.
Results and discussion
Visualization of PMVs and liposomes by imaging flow
cytometry
Platelets present in the PRP were visualized via fluorescent
microscopy. A phalloidin staining method revealed specific
actin cytoskeleton organization. When unactivated platelets
were placed on a siliconized surface, the abundant actin fila-
ments traced out a regular distribution resembling cobble-
stones, comprising central rings with a thin peripheral zone
(Fig 1a). A collagen-coated surface caused platelet activation
and PMV release (Fig 1b, c). Actin filaments were stellate
with actin streaks, which became more distinguishable after
thrombin activation (Fig 1c). Moreover, platelet aggregates
were observed after thrombin treatment. The average
unactivated adhered platelet diameter was between 1 and
3 μm (Fig. 1c), but was less for activated platelets (Fig 1b, c).
The ImageStreamX Mark II imaging cytometer detected
three EV populations in the supernatent containing activated
platelets. The entire number of PMVs in 500 μl of supernatant
was 20,612 (± 10,664) counts/μl. Most (98.5 %) of the PMVs
were gated between 0.13 and 0.22 μm according to the cali-
bration procedure used in the SSC and bright-field channels
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(Fig. 1d) [10]. The immunofluorescent staining method
demonstrated that a minority of the small PMVs (∼30 %)
were positive for annexin V (i.e., they presented
phosphatidylserine, PS); nevertheless, most of the
microvesicles (∼60 %) were double-positive for the antigens
CD9 (exosome-specific) and CD61 (platelet-specific)
(Fig. 1e, f). This observation was confirmed by a single
microvesicle analysis (Fig. 1g). Such diversity of EVantigens
is commonly observed in biological samples and may be use-
ful for EV profiling [10, 15].
In order to evaluate the sensitivity of the ISX system, two
populations of POPC and POPC/POPS liposomes were exam-
ined: 100-nm and 200-nm liposomes. The pure POPC lipo-
somes were less stable than the POPC/POPS liposomes, and
the 200-nm liposomes were more varied in size than the 100-
nm liposomes (Fig. 2a). ISX discrimination of liposomes with
respect to the SSC/bright-field distribution demonstrated dif-
ferences in relative scatter intensity between the polystyrene
calibrator beads and liposomes (Fig. 2b, c). The refractive
index of the PMVs is n = 1.39, which is why the site scatter
Fig. 1a–g Optical images of platelets and platelet-derived microvesicles
(PMVs). Platelets obtained from PRP (platelet-rich plasma) were placed
on siliconized (a) and collagen-coated (b, c) glass slides. Phalloidin stain-
ing revealed specific actin cytoskeleton organization. Thrombin activa-
tion produced more phalloidin-stained spots (c). Arrows indicate actin
streaks from activated platelets, which correspond to actin-rich PMVs.
ImageStreamX Mark II cytometry showed that most of the PMVs were
gated between 0.13 and 0.22 μm in sidescatter (SSC) and bright-field
channels (d). A minority (∼30 %) of the PMVs were positive for annexin
V (e); most of the PMVs were double-positive for the antigens CD9
(exosome-specific) and CD61 (platelet-specific) (f). Selected images of
microvesicles are shown in g. AFAlexa Fluor, PE phycoerythrin
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intensity is weaker for lipid vesicles, including liposomes [8,
32]. Moreover, the smaller liposomes (100 nm) were less dis-
tinguishable than the larger liposomes, confirming the notion
of a physical optical resolution cutoff of 200 nm for flow
cytometry methods [11]. In order to look for a correlation
between the fluorescence signal and SSC intensity, annexin
V staining of the POPC/POPS liposomes was performed. ISX
analysis did not find any relationship between those two var-
iables (see Figs. S1 and S2 in the BElectronic supplementary
material,^ ESM).
Visualization of immobilized PMVs by AFM
AFM imaging of silicon substrate functionalized with PAC-1
antibodies showed the successive immobilization of PMVs
released from thrombin-activated platelets (Fig. 3a). Smooth
oval objects ranging in size from 100 to 250 nmwere detected.
These findings were consistent with the results of imaging
flow cytometry, in which dimensions between the 0.13-μm
and 0.22-μm calibration beads were usually observed.
In order to characterize the molecular overlayer formed
during functionalization and PMV immobilization,
nanostructural parameters such as AFM height and feature
size were determined (Fig. 3b). The GOPS-modified silicon
substrate was characterized by an AFM height of 1.7 (± 0.2)
nm and a feature size of about 11 (± 2) nm, which are in good
accord with literature reports of silanized surfaces of this type
[23, 24, 33]. Incubation of the GOPS-modified surface with
PAC-1 antibody led to surface coverage and a distinct increase
in AFM height (of about 1.0 nm). The mean surface feature
size was 22 (± 5) nm, which corresponded to the apparent size
of the immobilized IgG monolayer (about 25 nm), and was
thought to be due to bordering caused by the AFM tip [34, 35],
indicating that individual monomers of pentameric IgM were
resolved in the AFM image. Subsequent blocking of free sites
on the surface with BSA barely changed the surface coverage,
since the nanostructural parameter values were largely un-
changed after the blocking procedure. Incubation of the
PAC-1-functionalized surface with PMVs resulted in
microvesicle immobilization. PMVs were clearly recogniz-
able in the AFM image, and the average height and size of
the recorded PMVs were 32 (± 7) nm and 230 (± 70) nm,
respectively (Fig. 3b). In turn, incubation of the functionalized
surface with human plasma led to a distinct change in the
molecular overlayer. Increases in both the AFM height (of
about 1 nm) and the feature size (to 40 (± 10) nm) were
observed, revealing that plasmamolecules had been adsorbed.
However, individual intact microvesicles were not visible in
the recorded AFM images after exposure to plasma. The most
abundant protein in human plasma is fibrinogen, the
Fig. 2a–d Visualization of multilamellar and/or unilamellar POPC and
POPC/POPS liposomes. The size distribution and stability of the lipo-
somes were analyzed using a Malvern Zetasizer Nano S particle size
analyzer. The POPC/POPS liposomes were more homogeneous in size
and more stable than the pure POPC liposomes (a). Overlaying 100-nm
(b) and 200-nm (c) POPC/POPS liposomes (blue) with the polystyrene
nanobeads (0.13, 0.22, 0.45, 0.88, and 1.33 μm) acquired by ISX
demonstrated that ISX resolved the 200-nm liposomes better. The differ-
ence in relative scatter intensity between these two types of particles was
only distinguishable for the 200-nm liposomes. Representative images of
objects stained with annexin V Pacific Blue showed that the annexin V
fluorescence was localized on liposomes (d). PB Pacific Blue, POPC 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, POPS 1-palmitoyl-2-
oleoyl-sn-glycero-3-phospho-L-serine sodium salt
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concentration of which ranges between 2 and 3 g/mL. PAC-1
is a specific IgM antibody against the gpIIb/IIIa (α2β3)
integrin complex, a receptor for fibrinogen and von
Willebrand factor [36]. It is possible that some of the
immobilized integrin complexes from plasma were able to
bind to fibrinogen on the functionalized surface. Another ex-
planation is the formation of fibrin and its combination with
proteins in the plasma to form the molecular overlayer [37].
Ellipsometry-determined thickness of the biomolecular
layer on the functionalized surface
The application of spectroscopic ellipsometry to determine
the thickness of the molecular overlayer formed on each
silicon substrate allowed us to examine the effects of each
step in the functionalization of the silicon surface and to
detect immobilized microvesicles. Ellipsometry is consid-
ered to be a sensitive method if the thin-film thickness is
within the wavelength range of the light used for measure-
ments—usually 5–1000 nm. This range is useful and pro-
duces good results in EV experiments. Since immobilized
PMVs do not form a coherent layer, the effective thickness
is related to the amount of PMVs on the surface rather than
the height of the immobilized PMV measured with AFM.
Firstly, the thickness of the native SiOx layer, 2.1
(± 0.1 nm), was obtained for the cleaned and hydrophilized
silicon substrate. Modification with GOPS yielded a mono-
molecular silane layer with a thickness of 0.76 (± 0.04) nm,
which is similar to corresponding values reported in the
literature [38]. The subsequent immobilization of PAC-1 an-
tibody led to surface coverage with an ellipsometric thick-
ness of the protein overlayer of 1.2 (± 0.2) nm. This value
allowed us to estimate the PAC-1 antibody surface density
using the protein mass density (1.37 g/cm3) as a scaling
factor. The evaluated surface coverage of 1.6 (± 0.3) mg/
m2 is relatively high compared to reported coverage values
for protein immobilized on GOPS-modified surfaces [23,
24] . This confirms the effective immobilization of PAC-1
antibody on the silicon substrate by covalent bonding.
Blocking the free surface sites with BSA hardly changed
the thickness of the protein overlayer. This agrees with our
AFM results, which also reveal that blocking has almost no
impact. The incubation of PAC-1 antibody-functionalized
substrates with plasma and the isolated PMV solution led
to significant increases in the ellipsometric thickness of the
biomolecular layer of 2.2 nm and 6.4 nm, respectively.
When the isolated PMV solution was used, the estimated
surface coverage with PMVs, as evaluated by assuming
the constant microvesicle height taken from AFM measure-
ments, was about 10 %, confirming the effective binding of
the PMVs with the surface. In order to examine the impact
of nonspecific adsorption on the measured ellipsometric
thickness, a negative control was performed, which involved
incubating a BSA-covered substrate with plasma and then in
a solution of isolated PMVs. The results obtained (white
columns in Fig. 4) confirm that the PMVs highly specifical-
ly bind to the functionalized substrates, but they also reveal
high levels of nonspecific plasma molecule adsorption. The
nonspecific binding of plasma proteins was gauged by com-
paring the difference in ellipsometric thickness between
PAC/BSA/plasma and PAC/BSA with the difference in
ellipsometric thickness between BSA and BSA/plasma.
This suggests that the ellipsometric measurement of the
thickness of the molecular overlayer on a functionalized sil-
icon substrate is a promising approach for estimating the
amount of microvesicles in a solution of isolated PMVs
rather than in plasma. The average number of PMVs accord-
ing to ISX was about 2,000 counts/μL.
Fig. 3a–b Representative AFM topographic micrograph of PMVs
immobilized on a functionalized silicon substrate (a); scan size is 2 ×
2 μm2. Plot (b) showing values of some structural parameters—AFM
height and feature size—of the biomolecular layer, as determined after
surface functionalization andmicrovesicle immobilization.Error bars are
standard deviations determined from five AFM images of the same
surface and measurements of 25 individual PMVs. BSA bovine serum
albumin, GOPS 3-glycidoxypropyl(trimethoxysilane), PAC IgM anti-
glycoprotein IIb/IIIa, PMVs platelet-derived microvesicles
Immobilization and detection of platelet-derived EVs 1115
Detection of immobilized PMVs by TOF-SIMS
TOF-SIMS spectrometry was applied to examine the molec-
ular compositions of the functionalized silicon substrates and
to perform the direct chemical detection of immobilized
microvesicles. TOF-SIMS ion fragments characteristic of pro-
teins and membrane lipids were analyzed (Fig. 5). The ion
fragment C10H11N2
+ (m/z 159) of tryptophan [39], an amino
acid that is much more abundant in the antibody (2.0 % for
IgG [40]) than albumins are (0.2 % for both BSA [41] and
HSA [39]), was taken as a TOF-SIMS signal that is charac-
teristic of the antibody. The intensity of this signal remains
stable after blocking and microvesicle immobilization,
confirming the irreversible functionalization of the surface
with the PAC-1 antibody. Signals originate from different
membrane phospholipids: C3H6NO2
+ (m/z 88) from the ami-
no acid serine, which is present in phosphatidylserine (PS)
[42]; C5H12N
+ (m/z 86) and C5H15PNO4
+ (m/z 184) from
phosphocholine [42, 43], which is present in phosphatidylcho-
line (PC) and sphingomyelin (SM); and C2H6N
+ (m/z 44) and
C2H7PNO3
+ (m/z 124), which are characteristic of phosphati-
dylethanolamine (PE) [42]. The excessive increases in all of
these signals after exposure to isolated PMVs confirm the
effective immobilization of PMVs on the surface and the pres-
ence of phospholipids on the microvesicle membrane. The
slight increases observed after exposure of the functionalized
silicon surface to the plasma indicate that circulating plasma
microvesicles are immobilized and that there is considerable
nonspecific adsorption of other plasma molecules. The
analysis presented here indicates that TOF-SIMS is a promis-
ing technique for detecting PMVs and for characterizing EV
lipid composition.
Limitation of the study
We are aware that our study has some limitations that may
influence the interpretation of the findings of our research.
One potential limitation is that the entire population of EVs
from human plasma and from activated platelets was used.
There are a number of studies showing that platelets can re-
lease a heterogeneous population of vesicles, including
plasma-membrane-derived microvesicles (PMPs), exosomes,
and other EV subcategories [44, 45]. EV formation can be
stimulated by platelet agonists (mostly thrombin and colla-
gen), mimicking true hemostasis. Among a number of univer-
sal platelet activators, Ca2+ ionophores also appear to stimu-
late EV formation in platelets [45]. In our study, we used the
commonly accepted platelet agonist thrombin at a concentra-
tion of 1 IU. This activator is less effective than a Ca2+
inonophore, especially for exosome formation. However, its
stimulatory activity is stronger than those of ADP and bacte-
rial lipopolysaccharide [45]. It is also important to note that
protein concentration and protein cargo vary depending on
microvesicle stimulation and the separation methods used.
Gradient centrifugation or single-step isolation by size-
exclusion chromatography allows enriched and more homo-
geneous subpopulations of EVs to be separated [45, 46]. The
resulting fractions are free of abundant plasma proteins and
are more regular in terms of size or density [45, 46].
Nevertheless, the PMV-specific surface antigen glycoprotein
IIb/IIIa has been detected in every platelet EV subpopulation
using mass spectrometry [45].
Conclusions
Activated platelets are the main source of microvesicles in
physiological and pathological processes, although the condi-
tions caused by disease are the most important stimuli for EV
shedding [2, 6, 18, 47]. Because of this, EVs are considered to
be the most promising potential biomarker for various dis-
eases, and the use of EVs as a biomarker has led to some
particularly spectacular clinical outcomes in cardiovascular
trials [3, 4].
The first goal of the present work was to create an appro-
priate surface for EV detection. The need for a highly specific
sensor for EVs, especially PMVs, is an emerging issue in
laboratory diagnostics and biomedical engineering [15, 17].
A variety of methods, including optical (nanoparticle tracking
analysis, high-resolution flow cytometry) and non-optical
(AFM, transmission electron microscopy, impedance-based
measurements, grating coupled interferometry) imaging
Fig. 4 Ellipsometric thickness of the biomolecular layer formed on a
silanized silicon substrate following functionalization of the substrate
and microvesicle immobilization (gray columns), as well as that for the
negative control (white columns). The evaluated thickness of the GOPS
layer was 0.78 ± 0.04 nm. BSA bovine serum albumin, GOPS 3-
glycidoxypropyl(trimethoxysilane), PAC IgM anti-glycoprotein IIb/IIIa,
PMVs platelet-derived microvesicles
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techniques have recently been developed and tested, but they
cannot be performed rapidly in many laboratories or used in
routine diagnostics [8–16]. An approach based on an
immunosensor surface could permit the efficient and specific
capture of EVs for further evaluation [15, 17]. In our study, we
developed a method of restraining both PMVs and circulating
plasma microvesicles in which monoclonal IgM antibody was
immobilized on a GOPS-modified silicon surface. By creating
this gpIIb/IIIa integrin complex-specific surface, we were able
to immobilize integrin-positive circulating PMVs, which
facilitated the characterization of the size (diameter), amount,
and lipid composition of the PMVs.
This work is the first to demonstrate phospholipid compo-
nents of PMVs using a TOF-SIMS approach. We confirmed
the presence on the surface with immobilized PMVs of EV-
specific phosphatidylserine (PS); phosphatidylethanolamine
(PE), which is abundant in the plasma membrane; and
sphingomyelin (SM), which is abundant in platelets. While
the phospholipidomes of platelets and PMVs were found to
be qualitatively and quantitatively similar, the lipid fraction of
Fig. 5 TOF-SIMS analysis of the biomolecular layer that formed on a
silanized silicon substrate after functionalization and microvesicle (PMV)
and plasma immobilization. Normalized intensities of secondary ions
characteristic for amino acids and phospholipids: C10H11N2
+, tryptophan
fragment; C3H6NO2
+, phosphatidylserine (PS) fragment; C5H12N
+, cho-
line fragment; C5H15PNO4
+, phosphocholine head group; C2H6N
+,
dimethylamide group; C2H7PNO3
+, phosphatidylethanolamine (PE) frag-
m e n t . B S A b o v i n e s e r u m a l b u m i n , G O P S 3 -
glycidoxypropyl(trimethoxysilane), PAC IgM anti-glycoprotein IIb/IIIa,
PC phosphatidylcholine, PE phosphatidylethanolamine, PMVs platelet-
derived microvesicles, PS phosphatidylserine, SM sphingomyelin, Ttp
tryptophan (an amino acid)
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blood microparticles was observed to be enriched with phos-
phatidylcholine lipids in another study [48]. That finding con-
trasts with the results of our TOF-SIMS analysis, in which
stronger signals were obtained from PC and PE lipids on a
surface with immobilized PMVs. Another interesting finding
of our work is the confirmation of the presence of SM in
PMVs. High concentrations of SM in the platelet lipid fraction
have previously been observed using biochemical methods
[49]. Unexpectedly, we did not observe a significant increase
in PS and PE on the surface with immobilized human plasma.
It was previously demonstrated that 20 % of the native
microvesicles in human plasma are derived from other com-
ponents, such as erythrocytes, leucocytes, and endothelial
cells [2]. We believe that circulating plasma microvesicles
have different lipid components from those in PMVs [48].
Our findings allow fresh insight into microvesicle lipidomics,
and can be applied in further investigations of EVs that aim to
characterize MVs with different origins and identify specific
biomarkers [3].
Finally, it is worth noting that imaging flow cytometry is a
refraction-limited technique. The use of polystyrene beads for
cytometer calibration does not overcome this inadequacy, and
the application of a more congruent material (calibrated lipo-
somes) highlighted this limitation for smaller objects (<200 nm
in size). Because of this limitation of ISX, ellipsometry could be
a more useful technique for analyzing EV immobilization.
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